Araştırma Makalesi


DOI :10.26650/experimed.1494644   IUP :10.26650/experimed.1494644    Tam Metin (PDF)

Apelin Levels According to the Site of Involvement in Inflammatory Bowel Diseases

Ezgi DeğerliSelcan CesurAhmet YavuzMahmut Said DeğerliZeynep Ermiş Karaali

Objective: Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), presents ongoing challenges in terms of diagnosis and management. With increasing treatment options, reliable markers for assessing treatment response have become crucial. This study explored the potential of apelin, a peptide hormone implicated in inflammation, as a biomarker for monitoring disease activity in patients with IBD undergoing colonoscopy.

Materials and Methods: The study included 91 patients who were followed up for IBD. Apelin levels were measured in serum, and the site of involvement was simultaneously examined by colonoscopy. Alternations of apelin levels depending on the location of involvement was also considered.

Results: Despite the widespread presence of apelin in the gastrointestinal system (GIS), our findings did not reveal significant differences in apelin levels among patients with varying colonoscopic involvement (p=0.73).

Conclusion: Although apelin has potential as a biomarker of gastrointestinal inflammation in IBD, its precise role and clinical applicability necessitate comprehensive studies involving larger patient populations. Future research on apelin and IBD could refine its utility in disease monitoring and enhance its diagnostic significance. 


PDF Görünüm

Referanslar

  • 1. Kofla-Dlubacz A, Pytrus T, Akutko K, Sputa-Grzegrzölka P, Piotrowska A, Dziçgiel P. Etiology of IBD-is it stili a mystery? Int J Mol Sci 2022; 23(20): 12445. google scholar
  • 2. Jarmakiewicz-Czaja S, Zielinska M, Sokal A, Filip R. Genetic and epigenetic etiology of ınflammatory bowel disease: an update. Genes (Basel) 2022; 13(12): 2388. google scholar
  • 3. Seyedian SS, Nokhostin F, Malamir MD. A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. J Med Life 2019; 12(2): 113-22. google scholar
  • 4. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 1998; 251(2): 471-6. google scholar
  • 5. Földes G, Horkay F, Szokodi I, Vuolteenaho O, Ilves M, Lindstedt KA, et al. Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. Biochem Biophys Res Commun 2003; 308(3): 480-5. google scholar
  • 6. Japp AG, Newby DE. The apelin-APJ system in heart failure: pathophysiologic relevance and therapeutic potential. Biochem Pharmacol 2008; 75(10): 1882-92. google scholar
  • 7. Susaki E, Wang G, Cao G, Wang HQ, Englander EW, Greeley GH Jr. Apelin cells in the rat stomach. Regul Pept 2005; 129(1-3): 37-41. google scholar
  • 8. Wang G, Anini Y, Wei W, Qi X, OCarroll AM, Mochizuki T, et al. Apelin, a new enteric peptide: localization in the gastrointestinal tract, ontogeny, and stimulation of gastric cell proliferation and of cholecystokinin secretion. Endocrinology 2004; 145(3): 1342-8. google scholar
  • 9. Pitkin SL, Maguire JJ, Bonner TI, Davenport AP. International Union of Basic and Clinical Pharmacology. LXXIV. Apelin receptor nomenclature, distribution, pharmacology, and function. Pharmacol Rev 2010; 62(3): 331-42. google scholar
  • 10. Mosli MH, Zou G, Garg SK, Feagan SG, MacDonald JK, Chande N, et al. C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis. Am J Gastroenterol 2015; 110(6): 802-20. google scholar
  • 11. Sipponen T, Kolho KL. Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease. Scand J Gastroenterol 2015; 50(1): 74-80. google scholar
  • 12. Guardiola J, Lobaton T, Rodnguez-Alonso L, Ruiz-Cerulla A, Arajol C, Loayza C, et al. Fecal level of calprotectin identifies histologic inflammation in patients with ulcerative colitis in clinical and endoscopic remission. Clin Gastroenterol Hepatol 2014; 12(11): 1865-70. google scholar
  • 13. Lu L, Wu D, Li L, Chen L. Apelin/APJ system: A bifunctional target for cardiac hypertrophy. Int J Cardiol 2017; 230: 164-70. google scholar
  • 14. Topuz M, Cosgun M, Akkuş O, Bulut A, Sen O, Topuz AN, et al. Effect of spironolactone on plasma Apelin-12 levels in patients with chronic systolic heart failure. Acta Cardiol Sin 2016; 32(6): 690-7. google scholar
  • 15. Tycinska AM, Lisowska A, Musial WJ, Sobkowicz B. Apelin in acute myocardial infarction and heart failure induced by ischemia. Clin Chim Acta 2012; 413(3-4): 406-10. google scholar
  • 16. Zarei S, Saidijam M, Karimi J, Yadegarazari R, Rezaei Farimani A, Hosseini-Zijoud SS, et al. Effect of resveratrol on resistin and apelin gene expressions in adipose tissue of diabetic rats. Turk J Med Sci 2016; 46(5): 1561-7. google scholar
  • 17. Kocer D, Karakukcu C, Ozturk F, Eroglu E, Kocyigit I. Evaluation of fibrosis markers: apelin and transforming growth factor-01 in autosomal dominant polycystic kidney disease patients. Ther Apher Dial 2016; 20(5): 517-22. google scholar
  • 18. Han S, Wang G, Qiu S, de la Motte C, Wang HQ, Gomez G, et al. Increased colonic apelin production in rodents with experimental colitis and in humans with IBD. Regul Pept 2007; 142(3): 131-7. google scholar
  • 19. Ge Y, Li Y, Chen Q, et al. Adipokine apelin ameliorates chronic colitis in Il-10-/- mice by promoting intestinal lymphatic functions. Biochem Pharmacol 2018; 148: 202-12. google scholar
  • 20. Desreumaux P, Ernst O, Geboes K, Gambiez L, Berrebi D, Müller-Alouf H, et al. Inflammatory alterations in mesenteric adipose tissue in Crohn’s disease. Gastroenterology 1999; 117: 73-81. google scholar
  • 21. Guedj K, Abitbol Y, Cazals-Hatem D, Morvan M, Maggiori L, Panis Y, et al. Adipocytes orchestrate the formation of tertiary lymphoid organs in the creeping fat of Crohn’s disease affected mesentery. J Autoimmun 2019; 103: 102281. google scholar
  • 22. Mantaka A, Kalyvianaki K, Kastritsi O, Kampa M, Koutroubakis IE. Increased serum apelin levels in patients with inflammatory bowel disease. Gastroenterology Insights 2024; 15(2): 255-65. google scholar

Atıflar

Biçimlendirilmiş bir atıfı kopyalayıp yapıştırın veya seçtiğiniz biçimde dışa aktarmak için seçeneklerden birini kullanın


DIŞA AKTAR



APA

Değerli, E., Cesur, S., Yavuz, A., Değerli, M.S., & Ermiş Karaali, Z. (2024). Apelin Levels According to the Site of Involvement in Inflammatory Bowel Diseases. Experimed, 14(2), 126-130. https://doi.org/10.26650/experimed.1494644


AMA

Değerli E, Cesur S, Yavuz A, Değerli M S, Ermiş Karaali Z. Apelin Levels According to the Site of Involvement in Inflammatory Bowel Diseases. Experimed. 2024;14(2):126-130. https://doi.org/10.26650/experimed.1494644


ABNT

Değerli, E.; Cesur, S.; Yavuz, A.; Değerli, M.S.; Ermiş Karaali, Z. Apelin Levels According to the Site of Involvement in Inflammatory Bowel Diseases. Experimed, [Publisher Location], v. 14, n. 2, p. 126-130, 2024.


Chicago: Author-Date Style

Değerli, Ezgi, and Selcan Cesur and Ahmet Yavuz and Mahmut Said Değerli and Zeynep Ermiş Karaali. 2024. “Apelin Levels According to the Site of Involvement in Inflammatory Bowel Diseases.” Experimed 14, no. 2: 126-130. https://doi.org/10.26650/experimed.1494644


Chicago: Humanities Style

Değerli, Ezgi, and Selcan Cesur and Ahmet Yavuz and Mahmut Said Değerli and Zeynep Ermiş Karaali. Apelin Levels According to the Site of Involvement in Inflammatory Bowel Diseases.” Experimed 14, no. 2 (Nov. 2024): 126-130. https://doi.org/10.26650/experimed.1494644


Harvard: Australian Style

Değerli, E & Cesur, S & Yavuz, A & Değerli, MS & Ermiş Karaali, Z 2024, 'Apelin Levels According to the Site of Involvement in Inflammatory Bowel Diseases', Experimed, vol. 14, no. 2, pp. 126-130, viewed 16 Nov. 2024, https://doi.org/10.26650/experimed.1494644


Harvard: Author-Date Style

Değerli, E. and Cesur, S. and Yavuz, A. and Değerli, M.S. and Ermiş Karaali, Z. (2024) ‘Apelin Levels According to the Site of Involvement in Inflammatory Bowel Diseases’, Experimed, 14(2), pp. 126-130. https://doi.org/10.26650/experimed.1494644 (16 Nov. 2024).


MLA

Değerli, Ezgi, and Selcan Cesur and Ahmet Yavuz and Mahmut Said Değerli and Zeynep Ermiş Karaali. Apelin Levels According to the Site of Involvement in Inflammatory Bowel Diseases.” Experimed, vol. 14, no. 2, 2024, pp. 126-130. [Database Container], https://doi.org/10.26650/experimed.1494644


Vancouver

Değerli E, Cesur S, Yavuz A, Değerli MS, Ermiş Karaali Z. Apelin Levels According to the Site of Involvement in Inflammatory Bowel Diseases. Experimed [Internet]. 16 Nov. 2024 [cited 16 Nov. 2024];14(2):126-130. Available from: https://doi.org/10.26650/experimed.1494644 doi: 10.26650/experimed.1494644


ISNAD

Değerli, Ezgi - Cesur, Selcan - Yavuz, Ahmet - Değerli, MahmutSaid - Ermiş Karaali, Zeynep. Apelin Levels According to the Site of Involvement in Inflammatory Bowel Diseases”. Experimed 14/2 (Nov. 2024): 126-130. https://doi.org/10.26650/experimed.1494644



ZAMAN ÇİZELGESİ


Gönderim03.06.2024
Kabul05.08.2024
Çevrimiçi Yayınlanma26.08.2024

LİSANS


Attribution-NonCommercial (CC BY-NC)

This license lets others remix, tweak, and build upon your work non-commercially, and although their new works must also acknowledge you and be non-commercial, they don’t have to license their derivative works on the same terms.


PAYLAŞ




İstanbul Üniversitesi Yayınları, uluslararası yayıncılık standartları ve etiğine uygun olarak, yüksek kalitede bilimsel dergi ve kitapların yayınlanmasıyla giderek artan bilimsel bilginin yayılmasına katkıda bulunmayı amaçlamaktadır. İstanbul Üniversitesi Yayınları açık erişimli, ticari olmayan, bilimsel yayıncılığı takip etmektedir.